Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) dropped 2.2% on Monday . The stock traded as low as $7.30 and last traded at $7.45, with a volume of 53,593 shares trading hands. The stock had previously closed at $7.62.

ORMP has been the subject of several research reports. Rodman & Renshaw reiterated a “buy” rating and issued a $25.00 target price on shares of Oramed Pharmaceuticals in a research note on Friday, May 13th. Aegis restated a “buy” rating and set a $18.00 price target on shares of Oramed Pharmaceuticals in a research note on Wednesday, May 18th. Finally, FBR & Co raised their price target on shares of Oramed Pharmaceuticals from $15.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, May 26th. Five research analysts have rated the stock with a buy rating, Oramed Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $22.00.

The company has a 50-day moving average price of $7.95 and a 200 day moving average price of $7.88. The firm’s market capitalization is $96.29 million.

Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.